Cambridge-based Enhanc3D Genomics, which develops disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, has appointed Hazel Jones as chief executive, after a six-month tenure as interim chief executive and chief operating officer.

Jones has more than 10 years’ senior leadership experience in oncology research and working across functions to develop partnerships aligned with complex operational procedures. She has worked in various roles within AstraZeneca, including executive product director of clinical data, and head of business planning and operations in oncology R&D. She was also head of combination therapies at Cancer Research UK.

Enhanc3D Genomics’ chairman Dr Chris Torrance said: [Jones’s] guidance as COO and interim CEO has been instrumental in driving Enhanc3D Genomics’ global operations, forming new connections and developing existing strategic partnerships. On behalf of the board, I congratulate Hazel and look forward to continuing to work with her during this exciting phase for the company.”

Jones added: “My time as COO and interim CEO has been highly rewarding, and I am now honoured and excited to have been appointed to continue to lead Enhanced Genomics as CEO. I am grateful for the trust placed in me by the board and look forward to continuing to lead the company through our pivotal transition period to full commercialisation of our 3D genomics platform.”